Business
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight’s AI-enabled medication persistence and adherence solutions and enable rapid scalability of high-impact programs, such as the Patient App from its c
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"image","alt":"BrightInsight","displaySize":"","headline":null,"caption":"BrightInsight","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/51a39d7869367803c3edd6687c20211b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DQV0bfh9VLuh9_YLxeAbEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/51a39d7869367803c3edd6687c20211b","width":300,"height":42}},"lazy":false},{"type":"text","content":"SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight’s AI-enabled medication persistence and adherence solutions and enable rapid scalability of high-impact programs, such as the Patient App from its collaboration with Sanofi and their partner, Regeneron, across a broad range of diseases and therapies globally.","length":611,"tagName":"p"},{"type":"text","content":"The economic and clinical burden of medication non-adherence represents an urgent and silent crisis within the global healthcare system. Despite the availability of life-saving therapies, adherence rates for chronic diseases hover at a staggering 50%1, a disparity that contributes to approximately 125,000 preventable deaths annually, and accounts for up to 25% of all hospitalizations in the United States2. This systemic failure carries a massive financial toll, generating between $100 billion and $300 billion3 in avoidable healthcare expenses each year due to unnecessary provider visits, emergency treatments, and prolonged hospital stays.","length":646,"tagName":"p"},{"type":"text","content":"BrightInsight is uniquely positioned to meaningfully impact this crisis by deploying digital health solutions that bridge the gap between prescription and persistence, transforming patient outcomes while significantly reducing the strain on healthcare resources.","length":262,"tagName":"p"},{"type":"text","content":"Says Kal Patel, BrightInsight’s CEO & Co-Founder, “We typically see 30-70% or more of invited patients participating in our deployed programs, with a similar perce...